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RegenerationSince last few years, an impressive amount of data has been generated regarding the basic
in vitro and in vivo biology of neural stem cells (NSCs) and there is much far hope for the success
in cell replacement therapies for several human neurodegenerative diseases and stroke. The dis-
covery of adult neurogenesis (the endogenous production of new neurons) in the mammalian
brain more than 40 years ago has resulted in a wealth of knowledge about stem cells biology
in neuroscience research. Various studies have done in search of a suitable source for NSCs
which could be used in animal models to understand the basic and transplantation biology
before treating to human. The difﬁculties in isolating pure population of NSCs limit the study
of neural stem behavior and factors that regulate them. Several studies on human fetal brain
and spinal cord derived NSCs in animal models have shown some interesting results for cell
replacement therapies in many neurodegenerative diseases and stroke models. Also the methods
and conditions used for in vitro culture of these cells provide an important base for their appli-
cability and speciﬁcity in a deﬁnite target of the disease. Various important developments and
modiﬁcations have been made in stem cells research which is needed to be more speciﬁed and
enrolment in clinical studies using advanced approaches. This review explains about the current
perspectives and suitable sources for NSCs isolation, characterization, in vitro proliferation and
their use in cell replacement therapies for the treatment of various neurodegenerative diseases
and strokes.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Cairo University.
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Neural stem cells (NSCs) are self-renewing, multipotent cells
that generate the main phenotypes of the nervous system [1].
The hallmark characteristics of NSCs are its ability to prolifer-
ate and generate multiple cell lineages, such as neurons, astro-
cytes, and oligodendrocytes both in vitro and in vivo [2].
Grafting of neural stem cells into the mammalian central
nervous system (CNS) has been performed for some decades
now, both in basic research and clinical applications for neuro-
logical disorders such as Parkinson’s, disease, Huntington’s
disease, stroke, and spinal cord injuries. Albeit the ‘‘proof of
principle’’ status that neural grafts can reinstate functional def-
icits and rebuild damaged neuronal circuitries, many critical
roadblocks have still to be overcome to reach clinical applica-
tions. Among these are the manifold immunological aspects
that are encountered during the graft–host interaction
in vivo. Different sources of stem cells have been proposed to
the spontaneous recovery of most CNS injuries, but they
mostly generate a restricted range of cell phenotypes. Induced
pluripotent stem cells (iPS) have been recently proposed for
autologous transplantation, but a major drawback of these
genetically manipulated cells is the high risk of cancer forma-
tion, mainly due to the uncontrolled integration of retroviral
vectors and recombination events. Therefore, the most feasible
candidates to clinical neurological applications are currently
the embryonic stem cells (ESCs) and adult somatic stem cells,
particularly NSCs. On the contrary, NSC are mostly consid-
ered as the optimal cell type for cell mediated therapy of neural
disorders because they share the same tissue origin of the dam-
aged cells, meant to replenish and are amenable to local envi-
ronmental cues able to commit their differentiation choice [3–
5]. Accordingly, NSC have been shown to exert multiple ther-
apeutic effects, such as secretion of neurotrophic factors and
cytokines, scavenging of toxic molecules, immunomodulation
of inﬂammatory milieu, where neural cell replacement plays
only a minor role in the recovery of CNS damage [6–9].Fig. 1 NSCs self-renewal and proliferation pathway.During the last decade, an enormous amount of informa-
tion has been generated regarding the basic in vitro and
in vivo biology of NSCs. In 1989, Sally described multipo-
tent, self-renewing progenitor and stem cells population in
the subventricular zone (SVZ) of the mouse brain. In 1992,
Reynolds and Weiss were the ﬁrst to isolate neural progeni-
tors and stem cells from the adult striatal tissue, including
the SVZ [10]. Now it is well known that the continuous pro-
duction of new neurons is facilitated by neural stem or pro-
genitor cells (NSCs/NPCs). NSCs are self renewing,
multipotent cells which possess the capability to differentiate
into any neural cell type by symmetric and asymmetric cell
division while progenitors are proliferative cells with a lim-
ited capacity for self-renewal and often considered as unipo-
tent [11,12] (Fig. 1). As our current knowledge predicts that
the production of new cells in the brain follows a multi-step
process during which newborn cells are submitted to various
regulatory factors and inﬂuence cell proliferation, matura-
tion, fate determination and survival. Progenitor cells iso-
lated from the forebrain can differentiate into neurons
in vitro, as was demonstrated by Reynolds and Weiss in
1992. There are many types of cells present in the forebrain
where NSCs are characterized by using multiple cell surface
or intracellular markers such as nestin, musashi 1, sox-2,
prominin-1 and intigrins either separately or in combination
[13].
Multiple studies have demonstrated that endogenous neu-
rogenesis responds to insults such as ischemic stroke, multiple
sclerosis or other neurodegenerative diseases and even brain
tumors, supporting the existence of remarkable plasticity
and signiﬁcant regenerative potential in the mammalian
brain. Today it is no more a far fetched hope, but a realistic
goal, to claim that NSCs will be an inexhaustible source of
neurons and glia for cell replacement therapies aimed for
the treatment of disorders affecting the brain and spinal cord.
Embryonic stem cells (ESCs) and stem cells from the fetal/
adult central nervous system (CNS) or other tissues might
all be suitable for the purpose of cell replacement therapy,
since they all have shown the capacity to differentiate into
multiple cell types of the adult CNS [14–16]. Researchers
have succeeded in recovering brain function in adult animal
models by transplantation of NSCs [17–19], indicating the
existence of a regulatory mechanism for stem cell biology in
the adult brain. Due to the enormous potential of NSCs in
the treatment of many devastating hereditary and acquired
neurological diseases extensive molecular proﬁling studies
have performed in search of new markers and regulatory
pathways.
Stem-cell-based therapies could potentially be beneﬁcial by
acting though several mechanisms: Cell replacement, where
transplants of cells are given to directly replace those that
are lost; trophic support, where the cells are used to promote
survival of affected neurons and endogenous repair of the dis-
eased brain areas; modulation of inﬂammation, which may be
involved in the disease process. Any stem-cell-based approach
for treating a neurodegenerative disorder must be proven to
work through one or more of these mechanisms [20]. Here,
we discuss the clinical translation of neural stem cells in the
treatment of various neurodegenerative disorders: Parkinson’s
disease, Alzheimer’s disease, Huntington’s disease, Amyotro-
phic lateral sclerosis, Spinal cord injury, Depression, brain tu-
mors and Stroke.
Table 1 Different sources of stem cells advantages and disadvantages for their applications in clinical practice.
BMSCs UCBSCs ESCs iPSCs fNPCs Spinal cord cells Adipose MSCs
Isolation Challenging Challenging Challenging Challenging Challenging Challenging Easy
Ethical issues Considerable – Signiﬁcant None Signiﬁcant Considerable Few
Pre-isolation storage X
p
X X X X ?
Post-isolation storage
p p p p p p p
Tumorigenicity X X
p p
X X X
Transfection
p p p p p p
?
Safety/risk
p p p
?
p p p
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NSCs can be obtained from skin [21–23], ESCs [24], embryonic
NSCs [25,26], bone marrow [27] and adipose-derived mesen-
chymal stem cells (MSCs) [28], induced pluripotent stem cells
(iPSCs) [29,30], fetal [31] and adult nervous systems [32–35].
These all sources have been used to prove their potential for
the treatment of several neurodegenerative diseases by generat-
ing the desired type of CNS cells; such as MSCs derived from
different sources have been used for the production of dopa-
mine neurons for the treatment of Parkinson’s disease [36].
Like this many other types of cell are also being used for their
application in neurodegenerative diseases [37–39] and stroke
[39,40]. But still there is need of getting more suitable source
for in vitro and in vivo trans-differentiation into the correct
phenotype (Table 1). In clinical applications the cultured/dif-
ferentiated NSCs should be screened for bacterial, viral or fun-
gal contaminations, complete media replacement with saline or
PBS (Ca/Mg free), viability and integrity, etc.
Isolation and in vitro expansion of NSCs
In vitro expansion of NSCs requires several growth factors
such as EGF, FGF and LIF for their self-renewal, prolifera-
tion [41,42] and other stimulatory substances (FCS) for lineage
differentiation [43,44]. Therefore, cell density, growth factor
addition, medium supplementation, passaging techniques and
timing are utter importance in the maintenance of culture con-
ditions. Any small change in any of these factors in cultures of
such heterogeneous cell populations can change the cells po-
tential and possibly select for subpopulations of cells exhibit-
ing similar properties to each other. NSCs are cultured
mainly by two ways either as neurospheres or as monolayer.Fig. 2 Subventricular zone of adult human brain. (A) Coronal view s
cytoarchitecture of SVZ, consisting of ependymal cell layer, hypocel
neuroblasts and transitional zone separating the SVZ from the striatuIn recent years, scientists have discovered a wide array of
stem cells that have unique capabilities to self-renew, grow
indeﬁnitely, and differentiate/develop into multiple types of
cells and tissues. Researchers now know that many different
types of stem cells exist but they all are found in very small
populations in the human body, in some cases 1 stem cell in
1,00,000 cells in circulating blood [45]. Several parts of the
body has been identiﬁed as rich sources for stem cells such
as SVZ in brain is a rich source of NSCs [33] (Fig. 2), bone
marrow [46] and umbilical cord blood (UCB) [17] for MSCs.
These sources are being used by researchers around the world
for their proper isolation, characterization and differentiation
potential both in vivo and in vitro. Many cell surface and intra-
cellular markers have been identiﬁed for the characterization
of NSCs isolated from various sources. But still there is need
to search for more accurate, reliable and speciﬁc marker to
identify NSCs and its lineages differentiated form NSCs,
MSCs or Hematopoietic stem cells (HSCs), etc. Genetic and
molecular biology techniques are extensively used to study
how cells become specialized in the organism’s development.
In doing so, researchers have identiﬁed genes and transcription
factors (proteins found within cells that regulate a gene’s activ-
ity) that are unique in stem cells.Neurosphere/Monolayer culture
In order to isolate and expand NSCs, Reynolds and Weiss
developed the neurosphere assay [10] which is the most com-
mon way to expand human NSCs in vitro. A neurosphere is
a free-ﬂoating, spherical cell aggregate potentially generated
from one single cell responsive to epidermal growth factor
(EGF) and/or basic-ﬁbroblast growth factor (bFGF) to divide
and generating daughter cells that are also responsive to thesehowing the lateral ventricles showing the cellular composition and
lular gap, astrocytic ribbon containing astrocytes and migrating
m rich in neurons.
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CO2 and 37 C temperature [47]. Neurosphere cultures are
considerably heterogeneous by nature. The neurosphere assay
can be used to assess the stem cell characteristics of self-renew-
al and multipotency [48]. To test for self-renewal, clonally de-
rived neurospheres are dissociated and then replated at clonal
density, in order to determine the cells’ capacity to form new
spheres, so called secondary sphere formation. To test for mul-
tipotency, clonally derived neurospheres are cultured under
differentiating conditions, in order to monitor the ability of
these cells to generate the three main cell types of the CNS,
i.e. neurons, astrocytes and oligodendrocytes [49].
Human NSCs can also be expanded as attached monolayer
cultures in the same environment of 37 C temperature and
5% CO2 [50]. Clonogenic assays, to establish stem cell proper-
ties, are more difﬁcult in attached monolayer cultures than for
neurosphere cultures, but have been achieved by tagging indi-
vidual cells with retroviral vectors [44,51]. Adherent NSCs
from fetal and adult forebrain generate a quite homogenous
population as assessed by both molecular and morphological
methods. Monolayer cultures have until recently not been very
successful for long-term culturing of human NSCs, unless the
cells were immortalized. However, the addition of the mitogens
EGF and FGF-2 to the deﬁned and reﬁned medium seems to
reduce the rate of apoptosis and sustain the proliferative
capacity of these cells for long-term [52].Characterization of NSCs
It is essential to thoroughly characterize the NSCs before start-
ing treatment, since isolated NSCs can become tumorigenic
after serial passaging and transplantation [53,54]. Over the
past few decades hematopoietic stem cells (HSCs) and progen-
itor cells have been identiﬁed by using monoclonal antibodies
directed against their surface markers, which allows rare pop-
ulations of cells to be enriched while remaining viable. In con-
trast to the detailed studies that have advanced our
understanding of HSCs, the lack of effective methodologies
for the prospective identiﬁcation or puriﬁcation of NSCs has
slowed research into their biology to be deﬁned experimentally
as neurosphere-initiating cells [10].
Researchers have also applied a genetic engineering ap-
proach that uses ﬂuorescence, but is not dependent on cell
surface markers. The importance of this new technique is that
it allows the tracking of stem cells as they differentiate or be-
come specialized. Scientists have inserted into a stem cell a
‘‘reporter gene’’ called green ﬂuorescent protein (GFP) [55].
The gene is only activated or ‘‘reports’’ when cells are undif-
ferentiated and is turned off once they become specialized.
Once activated, the gene directs the stem cells to produce a
protein that ﬂuorescence in a brilliant green color. This gene
encodes a C2H2 zinc-ﬁnger protein. Its highly-speciﬁc expres-
sion in pluripotent stem cells has been conﬁrmed in mouse
and human ES cells [56], making it one of the most famous
markers of pluripotency tested in various stem cells such as
multipotent adult progenitor cells [57] and amniotic ﬂuid cells
[58]. Researchers are now coupling this reporting method
with the ﬂuorescence activated cell sorting (FACS) and
microscopic methods described earlier to sort cells, identify
them in tissues, and now, track them as they differentiate
or become specialized.Rapid advances in the stem cell biology have raised appeal-
ing possibilities of replacing damaged or lost neural cells by
transplantation of in vitro-expanded stem cells and/or their
neuronal progeny. However, sources of stem cells, large scale
expansion, control of the differentiations, and tracking
in vivo represent formidable challenges. The ability to identify
hNSCs by brain imaging may have profound implications for
diagnostic, prognostic, and therapeutic purposes. Currently,
there are no clinical, high-resolution imaging techniques that
enable investigations of the survival, migration, fate, and func-
tion of unlabeled NSC and their progeny. Noninvasive track-
ing methods that have been successfully used for the
visualization of blood-derived progenitor cells include mag-
netic resonance imaging and radionuclide imaging using sin-
gle-photon emission computed tomography (SPECT) and
positron emission tomography (PET). The SPECT tracer In-
111-oxine is suitable for stem cell labeling, but for studies in
small animals, the higher sensitivity and facile quantiﬁcation
that can be obtained with PET are preferred [59].
These discovery tools are commonly used in research labo-
ratories and clinics today, and will likely play important roles
in advancing stem cell research. There are limitations, how-
ever. One of them is that single marker identifying pluripotent
stem cells, those stem cells that can make any other cell, has yet
to be found. As new types of stem cells are identiﬁed and re-
search applications of them become increasingly complex,
more sophisticated tools will be developed to meet investiga-
tors’ needs. For the foreseeable future, markers will continue
to play a major role in the rapidly evolving world of stem cell
biology.
The ﬁrst example of immune-selection using a surface anti-
gen was reported by Johansson et al. [60], who used an anti-
body to Notch1 to enrich NSCs from the adult mouse brain.
Subsequently, Uchida et al. [61] succeeded in isolating a popu-
lation enriched for human fetal NSCs by sorting CD133+,
CD34-, CD45- cells. Neurospheres on repeated passages pro-
duce self-renewing, proliferating and differentiating cells, typ-
ically presenting prominin-1 cell surface antigen (CD133)
and these cells are uniquely separated from the heterogenous
cell population directly by magnetic beads conjugated with
antibodies (MACS) or FACS by negative selection of CD34-
and CD45- antigen markers cells (CD133+ CD34-CD45-).
A list of positive and negative markers used to identify NSCs
and its lineages is listed in Table 2.
NSCs have been identiﬁed to differentiate into neuronal
and glial cell lineages. To evaluate the differentiation capacity
of NSCs, normally the cells are exposed to differentiation sig-
nals coming from animal serum at varying concentration of 1–
10% [44] or chemically deﬁned compounds such as Poly-L-
Ornithin, laminin or matrigel [43,49]. In some cases removal
of growth factors in conjugation with an adherent substrate
has been also added to promote NSCs differentiation [47]. Still
there is need for improved differentiation and enrichment pro-
cedures to get the highly pure populations of NSCs, glia and
neurons. One way to address this problem is to identify cell-
surface signatures that enable the isolation of these cell types
from heterogeneous cell populations by various techniques.
Cell surface marker expression has been described for the iden-
tiﬁcation and isolation of many neural cell types by FACS
from embryonic and adult tissue from multiple species. The
glycoprotein CD133 is a known stem/progenitor cell marker
in many tissues and has been used to isolate NSCs from human
Table 2 NSCs, NPCs and its lineage speciﬁc markers.
Type of cells Positive markers Negative markers
NSCs Prominin-1 (CD133), CD56 (NCAM), Nestin, Sox-2, Oct-4, Notch-2, ABCB1,
ABCG2, RBP1, RBP2, RBP7, HSPA4, HSPA9, HSPA14
CD34, CD45
Neuronal progenitors PSNCAM, P75 Neurotrophin Receptor –
Astrocytes progenitors CD44, A2B5 –
Olidodendrocyte progenitors NG2, PDGFR-a, Olig-2 –
Neurons MAP-2, Doublecortin (DCX), b-tubulin III, RNA Binding Protein
(HuC), Neuro D, Neu N
–
Astrocytes GFAP –
Oligodendrocytes Olig-1, Olig-4, Galactocerebrocide (Gal C) –
Neural stem cells in neural regeneration research 281brain [62]. In early 1970s neurobiologist kept their efforts to
establish a battery of neural cell-speciﬁc markers which would
serve studies of lineage and functional identiﬁcation both
in vivo and in vitro. Antibodies developed for intermediate ﬁl-
ament proteins have been extensively used for cell identiﬁca-
tion such as neurons can be characterized by their associated
neuroﬁlament protein Tuj1 (b tubulin-III) [63,64], astrocytes
by glial ﬁbrillary acidic proteins (GFAP) [65] and oligodendro-
cytes by O4 [66]. In brief, advances in understanding the struc-
ture and role of cell-speciﬁc markers have greatly increased
their usefulness in that they will allow functional aspects of
the brain to be studied in its developments, differentiation
and diseased states.
Major breakthroughs in stem cell research were made by
the identiﬁcation of proteins such as colony-stimulating factors
(CSFs) and cell-surface CD molecules. Proteins are key players
inside the cell. They have several diversiﬁed features that are
not easily predictable from gene sequences or transcription lev-
els. Therefore, proteome analysis is needed to analysis their
properties. Both basic and clinically oriented stem cell research
are confronted with many open questions that can be most efﬁ-
ciently answered by proteomics. For instance, the cell surface
proteins and signaling cascades of stem cells and their differen-
tiated progenies are largely unknown, as are the differentia-
tion-speciﬁc proteins that can be used as biomarkers of the
intermediate or terminal steps of cell differentiation, or dis-
criminate tumorigenic cells from the pool [67]. However, as a
corollary, great caution must be exercised in the interpretation
of changes in the expression of such markers.Table 3 Some recent clinical trials using human neural stem cells f
Trial title Trial no. Status Duratio
Human neural stem cell
transplantation in amyotrophic
lateral sclerosis (ALS)
NCT01640067 Recruiting 2012–20
Human spinal cord derived neural
stem cell transplantation
for the treatment of Amyotrophic
Lateral Sclerosis (ALS)
NCT01348451 Active, not
recruiting
2009–20
The long-term safety and eﬃcacy
follow-up study of subjects
who completed the phase I Clinical
Trial of Neurostem-AD
NCT01696591 Recruiting 2012–20
Molecular analysis of human
neural stem cells
NCT01329926 Enrolling by
invitation
2011–20Role of human NSCs transplantation therapy in the treatment of
neurodegenerative diseases and stroke
The nervous system, unlike many other tissues, has a limited
capacity for self-repair; mature nerve cells lack the ability to
regenerate, and NSCs, although they exist in the adult brain,
have a limited ability to generate new functional neurons in re-
sponse to injury. For this reason, there is great interest in the
possibility of repairing the nervous system by transplanting
new cells that can replace those lost through damage or dis-
ease. NSCs are extensively found in three areas of brain, the
SVZ of the lateral ventricle, the external germinal layer of
the cerebellum and the subgrannular zone of dentate gyrus
[32,68,69]. These sources of progenitor population can be
widely employed in the treatment of neurological disorders
[70]. In one report, it has been estimated that 1.3 million peo-
ple suffer from spinal cord injuries in USA [71]. As far as In-
dian sub continent is concerned, it is reported that every year
India gets over 20,000 cases of spinal cord injury patients [72].
New insights into the biology of NSCs have raised signiﬁcant
use of these cells for the treatment of various neurological dis-
eases, stroke and gliomas. Various reports and data in animal
models of neurologic diseases suggest that transplanted NSCs
may also attenuate deleterious inﬂammation, protect the CNS
from degeneration, and enhance endogenous recovery
processes.
Over the past few years, there has been continuous progress
in developing approaches to generate the types of human-de-or treating neurological diseases.
n Country Outcome
measure
16 Italy To verify safety and tolerability
of expanded human fetal neural stem cells
13 USA To determine the safety and
measurement of incidence for
adverse events in the ALS
13 Republic of
Korea
Changes in Alzheimer’s Disease
Assessment Scale-Cognitive
Subscale (ADAS-Cog) and
Caregiver-administered
Neuropsuchiatric Inventory
14 USA Neuronal diﬀerentiation into
dopaminergic neurons in Parkinson’s Diseased Brain
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ment therapy based on pathology in the respective diseases.
Patient’s speciﬁc cells that may be useful for transplantation
can now be produced from iPSCs [73–75]. The objective for
the grafted NSCs is either to stimulate and/or support the pro-
liferation, survival, migration, and differentiation of endoge-
nous cells, or, to replace the dying or dead endogenous cells.
In the prospect of cell replacement therapy, the implanted
NSCs must be able to survive and generate new neurons of
the appropriate types that functionally integrate into the dam-
aged host brain circuitry.
Stem cell-based approaches using umbilical cord blood,
bone marrow- derived HSCs and MSCs have already been ap-
plied in patients with spinal cord injury (SCI), with claims of
partial recovery [76]. Recent progresses in research on human
fetal brain derived neural precursors clearly indicate that theyTable 4 Summary of pathophysiology and NSCs based approache
S.no. Disease Cause S
1 Parkinson Degeneration of
dopaminergic neurons
H
R
p
2 Alzheimer Impaired formation of
hippocampal neurons
in subgranular zone of
the dentate gyrus
M
c
d
3 Spinal
cord injury
Loss of neurons and glia,
scar formation, demyelination
L
s
c
i
s
4 Huntington Defective huntingtin protein,
Progressive neurodegeneration
in striatum and cortex
L
d
a
b
p
5 ALS Weakness of cerebral cortex and
brain stem muscles
M
f
m
d
6 Multiple
sclerosis
Demyelination of neurons H
p
d
7 Brain tumor Uncontrolled cell division in brain I
h
a
i
8 Stroke Ischemic Ebolic Formation of embolus
in any part of the body
which travels in the
blood vessel
M
c
L
h
Thrombolic Formation of clot within
the
blood vessel
Hemorrhage Intracerebral bleeding caused
by the rupture of
a vessel in the brainmay play a very potential role in cell transplantation therapy
for neuronal regeneration in human brain and spinal cord.
Intrastriatal transplantation of human fetal primary tissue,
which is rich in post mitotic neurons and glia cells, has in clin-
ical trials provided proof-of-principle that neuronal replace-
ment can work in the human diseased brain [77] (Table 3).
A recent paradigm shift has emerged suggesting that the
beneﬁcial effects of stem cells may not be restricted to cell res-
toration alone, but also due to their transient paracrine ac-
tions. NSCs can secrete potent combinations of trophic
factors that modulate the molecular composition of the envi-
ronment to evoke responses from resident cells and have been
implicated in repair and regeneration of the CNS injury. Re-
cent directions in research on neurodegenerative diseases have
aimed to elucidate the production of neurotrophic factors, and
subsequent neuroprotective properties of neural stem cells.s for neurodegenerative diseases and stroke.
ymptoms Available
treatments
New strategies for
treatment
ypokinesia, Tremor,
igidity,
ostural instability
DA Antagonists,
Enzyme inhibitors,
Deep brain
stimulation, etc.
Transplantation
of hNSCs or
dopaminergic
neurons into
striatum or
substantia nigra
emory impairement,
ognitive
ecline, dementia
b-amyloid
immunotherapy
Transplantation
of hNSCs or
basal ﬁbroblast
producing NGF or
BDNF
oss of movement,
ensation and
ontrol below the
njured spinal
egment
No pharmacological
treatment
Transplantation of
OPCs, BMSCs and
hNSCs
oss of motor function,
ecline in mental
bilities and
ehavioral and
sychiatric problems
Fluoxetine, sertraline,
nortriptyline
Transplantation of
hNSCs producing
GDNF into the
striatum
uscle atrophy and
asciculations,
uscle spasticity,
ysarthria, dysphagia
Riluzole (Rilutek),
trihexyphenidyl or
amitriptyline
Delivery of motor
neurons, hNSCs and
hMSCs at multiple
sites along the spinal
cord
ypoesthesia,
aresthesia, ataxia,
ysarthria
Fingolimod (Gilenya) Transplantation of
hNSCs at the site of
injury
ntracranial
ypertension cognitive
nd behavioral
mpairment
Surgery radiotherapy
chemotherapy
Modiﬁed NSCs to
produce necessary
cytokines
otor, sensory or
ognitive impairments’,
oss of consciousness,
eadache, and vomiting
Tissue plasminogen
activator (t-PA)
and Aspirin
Cell replacement
therapy using hNSCs
or MSCs
Neural stem cells in neural regeneration research 283There is evidence suggesting that human neural stem cells
(NSCs), human UCBs and murine BM-MSCs secrete glial cell-
and brain-derived neurotrophic factors (GDNF and BDNF),
IGF-1 and VEGF, which may protect dysfunctional motor
neurons, thereby prolonging the lifespan of the animal into
which they are transplanted in animal models of neurodegen-
erative diseases [78–81]. The secretion of GDNF, BDNF and
NGF by NSCs has been implicated in increased dopaminergic
neuron survival in in vitro and in vivo models of PD, and the
release of anti-inﬂammatory molecules has been shown to
attenuate microglia activation, thereby protecting dopaminer-
gic neurons from death [82]. Based on this new insight, current
research directions include efforts to elucidate, augment and
harness NSCs paracrine mechanisms for CNS tissue regenera-
tion (Table 4).
Parkinson’s disease (PD)
Degeneration of nigrostriatal dopaminergic neurons is the
main pathology in PD, although other dopaminergic (DA)
and non-dopaminergic systems are also affected. Rigidity,
hypokinesia, tremor, and postural instability are the character-
istic symptoms of PD. Although motor symptoms can be trea-
ted relatively well with L-3,4-dihydrophenylalanin (L-DOPA),
DA agonists, enzyme inhibitors, and deep brain stimulation,
effective therapies for non-motor symptoms, such as dementia,
are lacking, and disease progression cannot be counteracted
[83]. Cell transplantation to replace lost neurons is a new ap-
proach to the treatment of progressive neurodegenerative dis-
eases (Fig. 3) [84]. Clinical trials with intrastriatal
transplantation of human embryonic mesencephalic tissue,
which is rich in postmitotic DA neuroblasts, have provided
proof of principle that neuronal replacement can work in PD
patients [85]. Replacement of dopaminergic neurons in pa-
tients with PD has spearheaded the development of this ap-
proach and was the ﬁrst transplantation therapy to be tested
in the clinic [86]. Experimental data from rodents and nonhu-
man primates demonstrated that dopaminergic neurons de-
rived from fetal ventral mesencephalon formed synaptic
contacts, released dopamine, and ameliorated PD-like symp-Fig. 3 Pathology of Parkinson’s disease andtoms when grafted intrastriatally. From these early studies
many questions have raised regarding the adverse effect, graft
rejection, optimal site of grafting and dose of cell delivery
which need to be solved before cell therapy. Human fetal de-
rived neural progenitors may provide ﬁrst line treatment giving
answers of these questions for repairing damaged neuronal cir-
cuitry and constitute a chance for patients who no longer de-
rive beneﬁt from pharmacological therapy. Fetal tissues
transplantation have provided convincing evidence that mid-
brain dopaminergic can survive long term in patients with
PD and can produce functionally relevant changes in dopami-
nergic functions [87]. The adult brain provides limited support
for neuronal differentiation, migration, and synaptic integra-
tion, and the process of transplantation itself might reduce sur-
vival by the induction of an inﬂammatory response. In
contrast to this fetal dopaminergic neurons transplanted into
the neonatal substantia nigra have the ability to regrow axons
into the striatum [88]. In the clinical perspectives some individ-
uals who have received transplants of fetal dopaminergic neu-
rons have shown clinical beneﬁt-that is beyond any doubt
[10,89].
Depression
In depression patient’s show a reduction in neurogenesis that
may contribute to debilitating psychological symptoms such
as low moods or impaired memory. It may occur only once
in a person’s lifetime, but more often it recurs throughout
the life. In preclinical work, Neuralstem’s lead pharmaceutical
compound, NSI-189, demonstrated clear evidence of increased
hippocampal volume in animals with a model of depression.
Neuralstem believes NSI-189 has the potential to reverse the
hippocampal atrophy associated with major depressive disor-
der and other related disorders, and to restore fundamental
brain physiology (Fig. 4).
It is one of the most important causes of disability world-
wide [90]. The high rate of inadequate treatment of the disor-
der remains a serious concern [91]. One of the cardinal features
of depression is its recurrent nature. Some patients experience
regular or periodic recurrence, whereas in other patientsNSCs based approach for cellular therapy.
Fig. 4 Pathology of Depression leading to the Alzheimer’s
disease.
284 S.K. Vishwakarma et al.recurrence is aperiodic. It is tempting to speculate that such
variation in mood might be attributable to the waning and
waxing of some neural process in the brain.
Chronic stress, infections, tissue damage and adverse events
of life has been subject of numerous investigations on the devel-
opment of depression and the work has been inﬂuenced by stud-
ies of the somatic and endocrine consequences of stress in
animals [92]. Life events preceding depression are variable and
there is no clear cut difference in the presence of events provok-
ing the onset of endogenous or non endogenous depression [93].
Epidemiological evidences for a genetic contribution, especially
for bipolar disorders, and heritability is estimated to be as high
as 80% indepression [94].However, the inheritance does not fol-
low the classical mendelian pattern, which suggests that a single
major gene locus may not––or at least only in few families––ac-
count for the increased intra-familial risk for the disorder.
The ﬁrst-generation anti-depressants such as tricyclic anti-
depressants (TCAs) and MAO inhibitors (MAOIs) have been
shown to be effective in alleviating the symptoms of depression.
Although both types of drugs have been used with great success
formanyyears, there are several undesirable side effects that lim-
it their application. Therefore various attempts are being madeFig. 5 Pathology of Alzheimer’s disease andtowards stem cell therapy to overcome the side-effects of phar-
macological treatment regimes and other complications.
Alzheimer disease (AD)
Alzheimer’s disease (AD) is the most common cause of demen-
tia in the elderly. The disease usually becomes clinically
apparent as insidious impairment of higher intellectual func-
tion with alteration in mood and behavior. Later, progressive
disorientation, memory loss, and aphasia become manifested,
indicating sever cortical disfunction. While pathogenic exam-
ination of the brain tissue remains necessary for the deﬁnitive
diagnosis of Alzheimer’s disease, the combination of clinical
assessment and modern radiological methods allows accurate
diagnosis in 80–90% of cases. The neuropathological hall-
marks of AD include ‘‘positive’’ lesions such as amyloid pla-
ques and cerebral amyloid angiopathy, neuroﬁbrillary tangles
and glial responses, and ‘‘negative’’ lesions such as neuronal
and synaptic loss [95]. The disease symptoms in AD could
partly be due to impaired formation of new hippocampal
neurons from endogenous NSCs in the subgranular zone of
the dentate gyrus, which is believed to contribute to mood
regulation, learning, and memory [96]. Memory impairment,
cognitive decline, dementia, neuronal and synaptic loss, neu-
roﬁbrillary tangles, and deposits of b-amyloid protein in se-
nile plaques involve the basal forebrain cholinergic system,
amygdala, hippocampus, and cortical areas in AD patients.
The situation for neuronal replacement aiming at functional
restoration in AD is extremely complex because the NSCs
would have to be predifferentiated in vitro to many different
types of neuroblasts for subsequent implantation in a large
number of brain areas. However, to give long-lasting symp-
tomatic beneﬁt, a cholinergic cell replacement approach
would require intact target cells, host neurons that the new
cholinergic neurons can act on, and they are probably dam-
aged in AD (Fig. 5).
Approaches to enhance neurogenesis and/or maturation
could be considered potential NSCs–based therapies for AD.
Clearance of brain b-amyloid has been proposed to be of value
in halting disease progression in AD. Active b-amyloid vacci-
nation in young AD mice, using as antigen a sequence of the
b-amyloid peptide, decreased b-amyloid burden and increased
hippocampal neurogenesis [97]. The ﬁndings indicate that ADNSCs based approach for cellular therapy.
Fig. 6 NSCs based approach of cellular therapy for Spinal cord
injury repair.
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the cognitive deﬁcits experienced by patients, suggesting that
normalization of the formation and maturation of new hippo-
campal neurons, for example, by active or passive b-amyloid
immunotherapy, could have therapeutic potential.
Stem cell–based gene therapy could deliver factors modify-
ing the course of AD and may be advantageous because of the
capacity of stem cells to migrate and reach large areas of the
brain [9,98]. Preclinical studies that provide a rationale for this
approach include one demonstrating that basal forebrain
grafts of ﬁbroblasts producing nerve growth factor (NGF),
which counteracts cholinergic neuronal death, stimulate cell
function and improve memory in animal models of AD [99].
Stem cells could also be engineered to carry other genes, such
as that encoding BDNF, which has substantial neuroprotective
effects in AD models [100].
Spinal cord injury (SCI) repair
The spinal cord has been an attractive target for cell-based
therapy, in part because of the dearth of available treatment
options for spinal cord injury (SCI), but also because of the ra-
pid pace of advance in our understanding of how to effect ax-
onal regeneration in the injured cord [101–103], without which
cellular replacement alone would be of limited beneﬁt. Patho-
logical changes after spinal cord injury are complex and in-
clude interruption of ascending and descending pathways,
loss of neurons and glial cells, inﬂammation, scar formation,
and demyelination. Loss of movement, sensation, and auto-
nomic control below the level of the injured spinal segment.
Pharmacological treatments are not effective in the treatment.
A wide array of stem cell transplantation strategies has been
tested for the potential to promote recovery in animal models
of SCI. These include, but are not limited to, oligodendrocytes
progenitor cells (OPCs) [104,105], bone marrow stromal cells
[106], Schwann cells [107], genetically-modiﬁed ﬁbroblasts
[108], embryonic-derived neural/glial stem cells [109], and fe-
tal/adult NSCs [110]. While cell transplantation in many of
these studies has been reported to result in improved recovery
of function, engraftment and survival of the transplanted pop-
ulation have been, in most cases, either partially investigated
or not addressed at all.
Different types of stem cells have been transplanted in in-
jured spinal cord and improved functional outcome in animal
models [76,111] probably through secretion of neutrotrophic
factors, remyelination of spared axons, or modulation of
inﬂammation. In clinical perspective, transplanted hNSCs
should give rise to matured neurons and oligodendrocytes to
promote functional recovery. Before neuronal replacement
strategies can be applied in patients with spinal cord injury,
it must be determined proliferation, differentiation into speciﬁc
types of neurons that can be directed to form appropriate syn-
aptic contacts (Fig. 6). High-purity OPCs generated from hu-
man embryonic stem cells in vitro have been shown to
differentiate into oligodendrocytes and give rise to remyelina-
tion after transplantation into the demyelinated mouse spinal
cord [112]. Recent studies on hNSCs transplantation into in-
jured mouse spinal cord have provided signiﬁcant improve-
ment to generate neurons and oligodendrocytes and induced
locomotor recovery [113]. In another study human hNSCs
transplanted into the injured rat spinal cord were found to dif-ferentiate into neurons that found exons and synapses and
establish contacts with post motor neurons [114]. Stem cell-
based approaches using umbilical cord blood, bone marrow-
derived HSCs, and NSCs have already been applied in patients
with a spinal cord injury, with claims of partial recovery [76].
How such approaches can be scaled up from rodents to hu-
mans and adapted to optimize the functional efﬁcacy of
hNSCs transplanted must also be determined prior to applica-
tion in patients.
Huntington’s disease (HD)
Huntington’s disease is an inherited fatal disorder in which the
abnormal processing of the defective huntingtin protein results
in progressive neurodegeneration, particularly in striatum and
cortex. Many of the symptoms of HD result from the loss of
inhibitory connections from the striatum to other structures
such as the globus pallidus. Multiple animal models of HD
have been developed to evaluate hNSCs therapy as a potential
treatment for the disease [115]. The commonly used R6/1
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ent CAG repeats, providing a close reproduction of HD [116].
The generation of these models involves the injection of
glutamic acid analogs (e.g., kainic, ibotenic, and quinolinic
acids) into the animal’s striatum to cause the excitotoxic cell
death of neurons in this structure and thus produce character-
istics similar to those of HD [18]. Human NSCs are then in-
jected intravenously and home to the injury site, where they
reduce striatal atrophy, differentiate into neurons, and im-
prove functional outcome [117]. In a rat model of HD, involv-
ing the stereotactic transplantation of human fetal NSCs
(identiﬁed by neurosphere formation) into the striatum, motor
function improved [118].
Many clinical trails using intrastriatal implantation of fetal
striatal tissues have done for the treatment of HD [119,120].
Recently researchers have identiﬁed that genetically modiﬁed
hNSCs that produce glial cell derived neurotrophic factor
(GDNF) protect striatal neurons from degeneration [121].
Amyotrophic lateral sclerosis (ALS)
Amyotrophy refers to the atrophy of muscle ﬁbers, which are
denervated as their corresponding anterior horn cells degener-
ate. Lateral sclerosis refers to hardening of the anterior and
lateral columns of the spinal cord as motor neurons in these
areas degenerate and is replaced by ﬁbrous astrocytes. Current
research has focused on excitotoxicity into the mechanisms
resulting in sporadic and familial types of ALS. This may oc-
cur secondary to overactivation of glutamate receptors, auto-
immunity to calcium ion channels, oxidative stress linked to
free radical formation, or even cytoskeleton abnormalities
such as intracellular accumulation of neuroﬁlaments. Apopto-
sis has emerged as a signiﬁcant pathogenic factor, and evidence
suggests that insufﬁcient vascular endothelial growth factor
may also be a risk factor for ALS in humans. However, no di-
rect mechanism has been identiﬁed and most researchers and
clinicians agree that various factors, possibly a combination
of some or all of the above processes, may lead to development
of ALS.
Due to abnormal function and degeneration of motor neu-
rons in the spinal cord, cerebral cortex, and brain stem muscle
weakness and death occurs within a few years in ALS. Yet
there is no effective treatment for ALS. Motor neurons have
been generated in vitro from stem cells from various sources,
including mouse and human embryonic stem (ES) cells [122],
NSCs derived from fetal rat spinal cord [123], human fetalFig. 7 NSCs based therapy for Amforebrain and human iPS cells [73]. For stem cell-based thera-
pies in ALS patients it must be shown that the cells can be
delivered at multiple sites along the spinal cord, integration
of stem-cell derived motor neurons into existing spinal cord
neural circuitries, receive appropriate regulatory input, and
able to extend there axons long distances to reinnarvate mus-
cles in humans. It also must be established that the differenti-
ation of the spinal motor neurons can be directed to the correct
cervical, thoracic, or lumber phenotype and that the ﬁnal cell
population projects to axial or limb muscles. For the treatment
of ALS using motor neurons such as carticospinal neurons,
which degenerate in ALS, also should be replaced for effective
and life saving restoration of function (Fig. 7). In several re-
ports glial cells carrying an ALS-causing genetic mutation im-
pair the survival of human ES cell-derived motor neurons in
culture [124]. Human fetal NSCs transplanted into the spinal
cord in a rat model of ALS have been found to protect motor
neurons and delay disease on set [80], probably has a result of
their neuronal progeny releasing GDNF and brain derived
neurotrophic factor (BDNF), dampening excitotoxicity, or
both. In another report cortical, GDNF-secreting hNSCs have
been shown to survive implantation into the spinal cord in a
rat modal of ALS, migrate into degenerating areas, and in-
crease motor neuron survival although they did not improve
limb function due to a lack of continued innervations of mus-
cle end plates [125,126]. Compared with direct gene transfer,
an advantage of cell based therapy is that production of the
trophic factor continues even if the disease process destroys
the endogenous cells. HSCs transplantation or delivery of
MSCs in order to alter the inﬂammation environment has al-
ready reached the clinic. Several studies clearly demonstrate
the improved therapy in ALS using MSCs as well as hNSCs
but more preclinical studies are needed prior to further patient
application.
Multiple sclerosis (MS)
Multiple Sclerosis (MS) is an inﬂammatory autoimmune and
demyelinating disease of the CNS. Demyelization causes mes-
sages to and from the brain to be slowed, distorted or stopped
altogether leading to the MS symptoms. There are two ap-
proaches that might be able to correct this damage. One is
to give drugs that make the NSCs already present work more
effectively. The other is to transplant new cells that will repair
the damage that the resident brain stem cells cannot. NSCs are
likely to be believed that they can have an effect throughyotrophic lateral sclerosis (ALS).
Fig. 8 Pathology and NSCs based cell therapy for multiple sclerosis in brain and spinal cord.
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(Fig. 8). For the second approach various animal model stud-
ies has been provided good improvement in NSCs based ther-
apies for MS.
One of the animal models of MS relies on the generation of
lesions in white matter tracts of the brain of rodents using lyso-
lecithin injections [127]. This model has been used to study the
survival and migration of transplanted progenitor cells to the
site of lesion and has shown that these cells survive and mi-
grate to injured areas in the brain, differentiate into oligoden-
drocytes, and start remyelination at the site of disease [128].
Another widely used animal model of MS is the experimental
autoimmune encephalomyelitis (EAE), in which inﬂammatory
demyelination is generated after the injection of an encephali-
togenic peptide [129]. In a rat model that uses X-ray irradia-
tion and Ethidium bromide exposure of the rat spinal cord,
transplanteation of human SVZ-derived NSCs of patients with
glioblastoma multiforme led to remyelination of axons and
recovery in the conduction velocities [130]. In a landmark
study of Pluchino et al. (2003) has demonstrated that adult
neural precursor cells promote multifocal remyelination and
functional recovery after intravenous or intrathecal injection
in a chronic model of multiple sclerosis [131]. This study re-
vealed the functional impairment caused by EAE was almost
abolished in transplanted mice, both clinically and neurophysi-
ologically. These results with MS animal models show that
transplanted hNSCs can improve disease progression and inte-
grate into injured tissues to aid in regeneration.
Brain tumors
Endogenous NSCs home to sites of tumor cell implantation in
a murine model of glioblastoma; this accumulation of NSCs
around the tumor correlates with the formation of smaller tu-
mors and longer survival [123]. Gliomas are the most frequent
type of brain tumor and have a miserable prognosis. Depend-
ing upon the presence of malignant features such as high cellu-
larity, nuclear atypia, mitosis, necrosis and endothelial
proliferation, gliomas have been classiﬁed into four grades: I
PA (pilocytic astrocytomas), II (low grade), III (anaplastic)
and IV GBM (glioblastoma). The prognosis of gliomas varies
with histological subtypes and grades therefore completesurgical resection of gliomas is virtually impossible due to their
invasive growth pattern. In adults glioblastoma multiforme
(GBM) is the most common and malignant primary brain tu-
mor, representing up to 50% of all primary brain gliomas. The
poor prognosis for glioma patients has not improved signiﬁ-
cantly over decades and need to develop new strategies for
the treatment in order to achieve maximal efﬁcacy with mini-
mal toxicity or side effects.
In the era of therapies designed to target speciﬁc molecular
lesions, a classiﬁcation based on histopathology does not pro-
vide sufﬁcient insight for patient stratiﬁcation. Therefore, great
efforts have been made to incorporate new information about
the molecular landscape of gliomas into novel classiﬁcations
that may potentially guide the treatment strategies. The cancer
stem-cell hypothesis proposes that malignant tumors are likely
to encompass a cellular hierarchy that parallels normal tissue
and may be responsible for the maintenance and recurrence
of glioblastoma multiforme (GBM) in patients. Identiﬁcation
and characterization of these cells may provide better under-
standing for glioma formation and their treatment strategies.
Glass and colleagues (2005) also suggested an antitumorigenic
property of NSCs by inducing apoptosis of tumor cells [132].
Exogenous NSCs migrate to gliomas whether implanted in
the brain or administered intravenously [133].
NSCs can be modiﬁed to deliver different therapeutic mol-
ecules [121]. In the case of brain tumors, NSCs have been engi-
neered to express cytosine deaminase [133] and thymidine
kinase [134], two prodrug-converting enzymes; these studies
showed that administration of engineered NSCs and the pro-
drug can decrease tumor growth. These studies provide impor-
tant evidence of another application for NSC-based therapy of
neurologic disease.
Stroke
Stroke is the leading cause of disability, and third leading
cause of death, in the industrialized world after cardiovascular
disease and cancer [135]. The pathology in stroke is very dy-
namic with initially necrotic that gradually is replaced by
apoptosis as well as the inﬂammatory response following the
insult. Stroke leads to motor, sensory or cognitive impair-
ments. There are no effective treatments in the sub-acute phase
Fig. 9 Pathology of stroke in brain and NSCs based cellular therapy.
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for recovery is valuable. Stroke can be divided into two major
types depending on the cause: ischemic and hemorrhagic.
Hemorrhagic stroke results from intracerebral bleeding caused
by a rupture of a vessel in the brain, which can cause physical
damage to the brain due to the build-up of pressure. Ischemic
stroke can in turn further be subdivided into embolic and
thrombotic. Thrombotic stroke is due to a clot gradually form-
ing within a vessel, while embolic stroke is results from an
embolus formed somewhere in the body that travels through
the blood stream, and blocks a vessel within the brain.
The brain has the highest demand of glucose and oxygen in
the body and is therefore particularly sensitive to reduced
blood ﬂow. Due to the deprivation of glucose and oxygen
caused by the stroke, a chain of detrimental events, including
cell respiration failure, uncontrolled glutamate release, cellular
edema, accumulation of free radical species, takes place, lead-
ing to cell death [136]. Within the ischemic core, cells quickly
die through necrosis, which does not require any energy, is
uncontrolled and usually involves several cells simultaneously
[137]. In the tissue peripherally surrounding the ischemic core,
the ischemic penumbra, cells gradually die through apoptosis,
which is an individual cell’s execution of an internal suicide
program. Apoptosis is either intrinsically or extrinsically acti-
vated and is ongoing for at least several days after the insult
in parallel to inﬂammation [138].
Current treatments for stroke are very limited; focusing on
removal of the clot in the acute phase, either by thrombolysis
alone or in combination with mechanical removal of the clot
[139] and not a single treatment has been successful in reversing
the effects of the chronic stroke. Physical therapies are oftenused
to promote functional recovery in long-term stroke patients, but
recovery is still incomplete. Therefore, reversal of symptoms
after a chronic stroke is a daunting problem that requires the
improvement of the patient’s lost function achieved by the
replacement of lost neurons and glia in the injured region, aswell
as the establishment of new functional connections. These
requirements call for bold new treatments that induce new neu-ral cells to differentiate and integrate into the circuitry that was
damaged by the stroke, the cell replacement therapy (Fig. 9).
Over the past few years large amount of data has been ac-
quired on NSCs treatment in animal models of stroke that
conﬁrms that NSCs are present throughout life and that
thousands of neurons are born on a daily basis in speciﬁc
zones of the brain, the SVZ, Dentate gyrus, hippocampus,
etc. [96]. In general, two broad approaches are needed to
be considered simultaneously in the development of cell
replacement therapy in stroke: the recruitment of endogenous
NSCs and exogenous stem cells transplanted into the affected
area. There are a lot of growth factors secreted by NSCs that
has the potential to be implemented as a therapeutic tool in
the recovery process after a stroke event, exploiting their neu-
roprotection and neurogenesis features [140]. In several stud-
ies NSCs derived from fetal brain tissue have been
transplanted showing some recovery in animal models of
stroke [141–143].
A variety of cell types have been tested in stroke models
such as human bone marrow cells, human umbilical cord
blood cells [144–146], rat trophic factor-secreting kidney cells
[146], and immortalized cell lines such as the human neuron-
like NT2N (hNT) cells [147] and MHP36, an embryonic mur-
ine immortalized neuroepithelial cell line [148]. Amongst all
these, NSCs have been proposed as a potential source of
new cells to replace those lost due to stroke, as well as a source
of trophic molecules to minimize damage and promote recov-
ery in clinical trials [147,149].
Expert commentary
Current status of the ﬁeld and recommendations for existing as
well as new paradigm choices
As the sources of NSCs are limited, they need to be maintained
in vitro for a long time to get the maximum number of cells
with same proliferative and differentiation capacity at the clin-
ical level. SVZ derived NSCs have vast regenerative potential
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less ethical issues. In vitro culture methods and conditions pro-
vide an important base for NSCs applicability and speciﬁcity
in a deﬁnite target of the disease. Neurosphere culture method
provides a better option for this purpose and to characterize
these cells and their lineages requires a better understanding
before transplantation. A cocktail of CD133+, CD34-/
CD45- has been proved as a better marker for identifying
the NSCs both in vitro and in vivo. The paracrine effect of
NSCs along with the growth factors provides more disciplinary
advantage for its proliferation, engraftment and homing at the
site of injury. However, a complete understanding of the com-
ponents, architectures and interaction in normal as well as
pathological neurogenic niche is paramount for the creation
of optimal condition in vitro to expand and culture NSCs
and use them in the treatment of multiple neurodegenerative
diseases.
Neurodegenerative disorders share a common pathological
mechanism involving aggregation and diposition of misfolded
proteins, leading to progressive CNS disorders. Although type
of aggregated proteins and their distribution for deposition
vary from disease to disease. Understanding the biology of ma-
jor neurological disorders is a challenging scientiﬁc problem
with enormous sociological and clinical relevance. The discov-
ery of anti-depressant drugs and the investigation of their
mechanism of action have revolutionized our understanding
of neuronal functioning and the possible mechanisms. In spite
of all the progress that has been achieved in the last decades,
we must be aware that there are still today considerable prob-
lems in understanding and treating severe neurological disor-
ders, and knowing the cause of treatment-resistant.
Although NSCs cell therapy seems to be a promising devel-
opment for a number on neurological diseases, transplantation
of NSC into the CNS is from an immunological viewpoint a
true challenge both for the host as well as for the donor cells.
Moreover more experiments are necessary to fully elucidate
the mechanisms underlining the interactions between stem cells
graft and host immune system.
Stem cell therapy and cell regenerative approaches to neu-
rological diseases can be divided into a number of categories
depending upon the target neurological disease. These diseases
include those caused by acute injury, chronic neurodegenera-
tive disorders, chronic inﬂammatory and immunologically
mediated conditions, and genetic diseases that present in child-
hood. One of the reason for failure or neuroprotective treat-
ments in an acute injury has been the need to start treatment
early, where cell-based therapeutic approaches provide a better
option. NSCs from various sources have shown effectiveness in
improving motor function in several neurodegenerative dis-
eases and stroke in animal experiments and clinical trial stud-
ies. However, factors that control the differentiation, survival,
and maturation of stem cells in the context of a host degener-
ative brain must be more thoroughly understood before stem
cell therapy will prove to be a robust and safe strategy that
can be transferred to the clinic. Furthermore, long-term and
large scale multicenter clinical studies are required to deter-
mine further the precise therapeutic effect of stem cell trans-
plantation however; various ongoing clinical trails using
hNSCs provide us better hope towards development of cellular
therapies for neurological diseases.
The types of nervous system diseases that represent the best
targets for stem cell-based therapies are those that would beimproved by the transplant or induced replacement of a lim-
ited number of cell types. Parkinson’s disease, sensory disor-
ders, and glial diseases fall into this category and could
potentially be cured by a cell-replacement therapy. Motor sys-
tem disorders and spinal cord injuries are more complex, but
given their severity and lack of current treatment options, it
can be argued that any improvement in function would be of
great beneﬁt using NSCs. There are nervous system disorders
that do not currently make good targets for cell replacement
therapies because the associated neurodegeneration is too
widespread and diffuse. Alzheimer’s disease is one example,
and it is unlikely to be ameliorated by adding more cells to
the system. However, Alzheimer’s research could beneﬁt enor-
mously from disease-speciﬁc cells derived from NSCs that
could be used to study the degeneration of neurons in vitro.
The prospect of using stem cells to intervene in neurodegener-
ative disease is promising, but given the complexities of the
nervous system, progress will likely continue in measured
steps. To move the research toward useful therapies, it is crit-
ical to access the efﬁcacy of any experiment involving human
or animal subjects to be performed using a double-blind pla-
cebo-controlled method.
Although there is currently no stem cell–based treatment
for diseases of the nervous system, the ﬁeld has moved much
closer to making this goal a reality. Progress has been driven
by major jumps in our understanding of how neuronal sub-
types and glia develop in vivo and in vitro. When there is a lack
of rigorous controls, it is easy to falsely attribute an observed
improvement to an incorrect cause. Finally, it is important to
have scientiﬁc meetings to communicate both positive and neg-
ative results, as well as successes and cautionary tales. Despite
the molecular differences between neurodegenerative diseases,
their eventual stem cell therapies will likely share many fea-
tures; Information gleaned in one ﬁeld can drive forward pro-
gress in the others.Concluding remarks
All together, NSCs research is one of the most exciting ﬁelds
of modern neuroscience and there is still a long way to go
before applying these cells in safety and efﬁcacy to cure var-
ious neurodegerative diseases and stroke. It is also very
important to understand the real impact of NSCs integra-
tion, engraftment and survival in normal as well as diseased
brain. To this regard, the future development of more
appropriate cellular therapeutic strategies will be needed to
efﬁciently recruit endogenous or exogenous NSCs; one of
the most important future challenges for basic and clinical
research.
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